Toussirot Eric, Vauchy Charline, Binda Delphine, Michel Fabrice
Clinical Investigation Center in Biotherapy, Intitut National de la Santé et de la Recherche Médicale CIC-1431; Fédération Hospitalo-Universitaire Integrated Center for Research in inflammatory Diseases; Department of Rheumatology, University Hospital of Besançon, Besançon, France; Department of Therapeutics; Equipe d'accueil EA 4266: "Pathogenic Agents and Inflammation", University of Franche-Comté
Clinical Investigation Center in Biotherapy, Intitut National de la Santé et de la Recherche Médicale CIC-1431.
Drug Des Devel Ther. 2016 Jul 1;10:2087-94. doi: 10.2147/DDDT.S107587. eCollection 2016.
Axial spondyloarthritis (Ax SpA) refers to chronic inflammatory rheumatic diseases that mainly affect the axial skeleton, leading to erosions and new bone formation in the sacroiliac joints and/or the spine. Ax SpA includes the radiographic form of the disease, ie, ankylosing spondylitis (AS), and the nonradiographic Ax SpA (non-Rx Ax SpA) forms. Anti-tumor necrosis factor alpha (TNFα) agents are used in the treatment of Ax SpA in patients who do not respond to or are intolerant to nonsteroidal anti-inflammatory drugs. In these patients, anti-TNFα agents show promising results by targeting the inflammatory process and providing symptomatic relief. Golimumab is a fully human anti-TNFα agent that is currently approved for the treatment of both AS and non-Rx Ax SpA in Europe. This review focuses on the results of clinical trials with golimumab for the treatment of AS (GO-RAISE studies) and non-Rx Ax SpA (GO-AHEAD study) and on the effects of this agent on imaging findings (radiographic progression, magnetic resonance imaging inflammation) as well as on biological parameters. Overall, golimumab is a valid therapeutic option in patients with AS and non-Rx Ax SpA in Europe.
轴性脊柱关节炎（Ax SpA）是指主要影响中轴骨骼的慢性炎症性风湿性疾病，可导致骶髂关节和/或脊柱出现侵蚀及新骨形成。Ax SpA包括疾病的影像学形式，即强直性脊柱炎（AS），以及非影像学Ax SpA（非放射学Ax SpA）形式。抗肿瘤坏死因子α（TNFα）药物用于治疗对非甾体抗炎药无反应或不耐受的Ax SpA患者。在这些患者中，抗TNFα药物通过针对炎症过程并提供症状缓解显示出有前景的结果。戈利木单抗是一种全人源抗TNFα药物，目前在欧洲已获批用于治疗AS和非放射学Ax SpA。本综述重点关注戈利木单抗治疗AS（GO-RAISE研究）和非放射学Ax SpA（GO-AHEAD研究）的临床试验结果，以及该药物对影像学表现（放射学进展、磁共振成像炎症）和生物学参数的影响。总体而言，在欧洲，戈利木单抗是AS和非放射学Ax SpA患者的一种有效治疗选择。
